DMAAR · Drugs Made In America Acquisition Corp. Ordinary Shares

The filing details two material agreements entered into on April 22, 2026. First, an updated Statement of Work with Titan Advisory Services LLC confirms that CFO Saleem Elmasri's services and $3,500 monthly compensation remain unchanged, but clarifies that unpaid amounts accrue as binding obligations. Notably, instead of the originally promised 100,000 shares, Titan's designated recipient (Elmasri) will receive 175,000 ordinary shares, earned upon execution of a definitive agreement for the company's initial business combination and issued within ten days of closing. Second, a CEO Compensation Agreement with Aleutian Equity Holdings LLC (Roger Bendelac's vehicle) sets monthly compensation at $4,500, with $2,500 payable currently and up to $2,000 deferrable based on cash flow; deferred amounts also accrue. Bendelac is entitled to 250,000 ordinary shares under the same vesting and issuance terms. Both equity grants are contingent on a future business combination, aligning executive incentives with deal completion. The agreements include standard indemnification, liability limitation, and dispute resolution provisions. These arrangements are significant as they formalize executive compensation and equity incentives, potentially impacting shareholder dilution upon a business combination.